Acumen Pharmaceuticals In... (ABOS)
Acumen Pharmaceuticals Inc. (ABOS) Stock Price, Analysis & Data
| Bid | 2.14 |
| Market Cap | 221.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -105.04M |
| Beta | 0.33 |
| EPS (ttm) | -1.64 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.14 |
| P/B (ttm) | 3.87 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 11, 2026 |
| Ask | 3.57 |
| Volume | 422,989 |
| Avg. Volume (20D) | 460,596 |
| Open | 2.79 |
| Previous Close | 2.74 |
| Day's Range | 2.79 - 3.09 |
| 52-Week Range | 1.21 - 3.60 |
| Analyst | Strong Buy |
| Price Target | 8 (161.44%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcu...
Financial Performance
In 2025, Acumen Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -121.33M, an increase of 18.57%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for ABOS stock is "Strong Buy". The 12-month stock price forecast is 8, which is upside of 161.44% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
